Special Edition: The Cardiovascular Outcome Trials – Origin and Perspective
DOC Updates21 Loka 2025

Special Edition: The Cardiovascular Outcome Trials – Origin and Perspective

In this special series on The Cardiovascular Outcome Trials our host, Dr. Neil Skolnik will discuss the history and importance of the Cardiovascular Outcome Trials for diabetes medications . In Part 1 we discuss an historical perspective with Dr. Steven Nissen and how this has lead to the CVOTs that change the way we practice from EMPA-REG in 2015 to SURPASS-CVOT in 2025. This special episode is sponsored with support from Lilly.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Steven Nissen, M.D., Chief Academic Officer of the Heart and Vascular Institute at the Cleveland Clinic and Professor of Medicine at the Clevland Clinic Lerner College of Medicine.

Selected references:

Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2005;294:2581-2586

Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (ADOPT). N Engl J Med 2006;355:2427­43.

DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096

Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007;356:2457-2471.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(100)

Beyond Diabetes and Obesity: Expanding Applications of Incretin Biology

Beyond Diabetes and Obesity: Expanding Applications of Incretin Biology

You know how GLP-1s impact diabetes and weight loss. But what about coronary disease treatment and prevention? Liver disease? Heart failure? Osteoarthritis? Sleep apnea? In this special episode, Dr. N...

6 Loka 32min

T2D & Bone Density, Microarchitecture, & Strength; Early Weight Loss, Glucose Tolerance, & Long-Term Mortality/CVD Risk; and more!

T2D & Bone Density, Microarchitecture, & Strength; Early Weight Loss, Glucose Tolerance, & Long-Term Mortality/CVD Risk; and more!

Welcome to the latest episode (October 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic diseas...

24 Syys 32min

Sarcopenic Obesity & T2D, Cumulative BMI Burden From Childhood to Adulthood & Risk of Metabolic Multimorbidity, and more!

Sarcopenic Obesity & T2D, Cumulative BMI Burden From Childhood to Adulthood & Risk of Metabolic Multimorbidity, and more!

Welcome to the latest episode (September 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic dise...

14 Syys 24min

Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone

Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone

Uncontrolled and resistant hypertension is more common than we think. In the second episode of this special three-part series, Dr. Neil Skolnik discusses management strategies, but also explores our n...

8 Syys 39min

Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)

What is the difference between MASH and MASLD? In this special episode, Dr. Neil Skolnik breaks down these conditions, which affect insulin resistance of the liver, an area of increasing concern for p...

3 Syys 22min

Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance

Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance

Weight maintenance is a challenging topic for both clinicians and patients. In this special episode, Neil Skolnik is joined by Jamie Almondoz, MD, who discusses the toxic narratives that have historic...

24 Elo 32min

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates ...

17 Elo 33min

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE...

10 Elo 35min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
aamukahvilla
vakeva-elama-viisaampi-mieli-vahvempi-keho
rss-pitaisko-erota
psykopodiaa-podcast
rss-kuumilla-aalloilla
meditaatiot-suomeksi
voi-hyvin-meditaatiot-2
rss-pt-paahtio
rss-terapiaklubi
tiedenaiset-podcast
rss-uplevel-by-sonja-hannus
selviytyjat-tarinoita-elamasta
rss-narsisti
terapiassa
rss-mighty-finland-podcast
paritellen
katilon-kahvitunti
rss-sanelunpurku-podcast
rss-hereilla